Cargando…

Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience

Background. KRAS mutation is an important predictive and prognostic factor for patients receiving anti-EGFR therapy. An expanded KRAS, NRAS, BRAF, PIK3CA mutation analysis provides additional prognostic information, but its role in predicting bevacizumab efficacy is unclear. The aim of our study was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baltruškevičienė, Edita, Mickys, Ugnius, Žvirblis, Tadas, Stulpinas, Rokas, Pipirienė Želvienė, Teresė, Aleknavičius, Eduardas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lithuanian Academy of Sciences Publishers 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924637/ https://www.ncbi.nlm.nih.gov/pubmed/28356789 http://dx.doi.org/10.6001/actamedica.v23i1.3267

Ejemplares similares

Rhabdoid Carcinoma of the Rectum
por: Samalavicius, Narimantas Evaldas, et al.
Publicado: (2013)

Down-regulation of miRNA-148a and miRNA-625-3p in colorectal cancer is associated with tumor budding
por: Baltruskeviciene, Edita, et al.
Publicado: (2017)

Hepatoid adenocarcinoma of the stomach with PIK3Ca mutation during pregnancy: A case report with molecular profile
por: Ranceva, Anastasija, et al.
Publicado: (2021)

Aberrant pancreas adenocarcinoma in the stomach: A case report and literature review
por: Petrauskas, Vidas, et al.
Publicado: (2023)

Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer
por: Takahashi, Naoki, et al.
Publicado: (2014)

Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance
por: Módos, Orsolya, et al.
Publicado: (2016)

Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients
por: Guo, Fang, et al.
Publicado: (2018)

KRAS, NRAS, BRAF, PIK3CA, and AKT1 signatures in colorectal cancer patients in south-eastern Romania
por: Brinzan, Costel Stelian, et al.
Publicado: (2022)

Two Multiplex Assays That Simultaneously Identify 22 Possible Mutation Sites in the KRAS, BRAF, NRAS and PIK3CA Genes
por: Lurkin, Irene, et al.
Publicado: (2010)

Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study
por: Palomba, Grazia, et al.
Publicado: (2016)

KRAS , NRAS , BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients
por: Mirzapoor Abbasabadi, Zohreh, et al.
Publicado: (2023)

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
por: Pasca, Sergiu, et al.
Publicado: (2019)

Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases
por: Zhang, Jing, et al.
Publicado: (2015)

KRAS/NRAS Mutations Associated with Distant Metastasis and BRAF/PIK3CA Mutations Associated with Poor Tumor Differentiation in Colorectal Cancer
por: Zeng, Juanzi, et al.
Publicado: (2023)

A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer
por: Kawazoe, Akihito, et al.
Publicado: (2015)

Development of a Cardio-Oncology Service in Lithuania: Prediction, Prevention, Monitoring and Treatment of Cancer Treatment-Induced Cardiotoxicity
por: Čiburienė, Eglė, et al.
Publicado: (2022)

Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit
por: Bando, Hideaki, et al.
Publicado: (2013)

Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer
por: Gökmen, İvo, et al.
Publicado: (2023)

EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas
por: BUJKO, MATEUSZ, et al.
Publicado: (2014)

Effectors of Epidermal Growth Factor Receptor Pathway: The Genetic Profiling of KRAS, BRAF, PIK3CA, NRAS Mutations in Colorectal Cancer Characteristics and Personalized Medicine
por: Shen, Yinchen, et al.
Publicado: (2013)

Clinical, Pathological and Molecular Insights on KRAS, NRAS, BRAF, PIK3CA and TP53 Mutations in Metastatic Colorectal Cancer Patients from Northeastern Romania
por: Afrăsânie, Vlad-Adrian, et al.
Publicado: (2023)

Association of KRAS, NRAS, BRAF and PIK3CA gene mutations with clinicopathological features, prognosis and ring finger protein 215 expression in patients with colorectal cancer
por: Wu, Jing-Bo, et al.
Publicado: (2023)

Asymptomatic primary tumour in incurable metastatic colorectal cancer: is there a role for surgical resection prior to systematic therapy or not?
por: Samalavicius, Narimantas E., et al.
Publicado: (2016)

Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
por: Hsu, Hung-Chih, et al.
Publicado: (2016)

KRAS, NRAS, and BRAF mutations in plasma cell myeloma at a single Korean institute
por: Kim, Yonggoo, et al.
Publicado: (2020)

KRAS/NRAS/BRAF Mutation Rate in Saudi Academic Hospital Patients With Colorectal Cancer
por: Saharti, Samah
Publicado: (2022)

High prevalence of unusual KRAS, NRAS, and BRAF mutations in POLE ‐ hypermutated colorectal cancers
por: Favre, Loetitia, et al.
Publicado: (2022)

KRAS, NRAS, BRAF signatures, and MMR status in colorectal cancer patients in North China
por: Lian, Shen-Yi, et al.
Publicado: (2023)

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
por: Manca, Antonella, et al.
Publicado: (2015)

KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study
por: Negru, Serban, et al.
Publicado: (2014)

Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers
por: Yang, Qiwei, et al.
Publicado: (2018)

The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
por: Eklöf, V, et al.
Publicado: (2013)

Next-generation sequencing-based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her-2 and TP53 mutations in patients with non-small cell lung cancer
por: Jing, Changwen, et al.
Publicado: (2018)

FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy
por: Kompier, Lucie C., et al.
Publicado: (2010)

Mutational frequency of KRAS, NRAS, IDH2, PIK3CA, and EGFR in North Indian gallbladder cancer patients
por: Sharma, Aarti, et al.
Publicado: (2017)

Detection of KRAS, NRAS and BRAF by mass spectrometry - a sensitive, reliable, fast and cost-effective technique
por: Kriegsmann, Mark, et al.
Publicado: (2015)

KRAS, NRAS, BRAF, HER2 and Microsatellite Instability in Metastatic Colorectal Cancer – Practical Implications for the Clinician
por: Afrăsânie, Vlad-Adrian, et al.
Publicado: (2019)

Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer
por: Bożyk, Aleksandra, et al.
Publicado: (2021)

KRAS, NRAS, BRAF, HER2 and MSI Status in a Large Consecutive Series of Colorectal Carcinomas
por: Martianov, Aleksandr S., et al.
Publicado: (2023)

KRAS, BRAF and PIK3CA Status in Squamous Cell Anal Carcinoma (SCAC)
por: Casadei Gardini, Andrea, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_li9kfpmaeor21s4cdlg9fmtcvm